FDA clears expanded access for promising pancreatic cancer drug
08/05/2026
FDA has issued a “safe to proceed” letter authorizing expanded access to the investigational pancreatic cancer therapy daraxonrasib for patients
FDA has issued a “safe to proceed” letter authorizing expanded access to the investigational pancreatic cancer therapy daraxonrasib for patients
Estudio de combinación semanal A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of
Suppressing a sneeze may have led to a spontaneous leak of cerebrospinal fluid (CSF) and air entering the skull of
Clinical takeaway: SSRIs and SNRIs remain first-line for anxiety disorders, while benzodiazepines should be reserved for short-term bridge use given